Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

Amgen gets approval for arthritis drug biosimilar

By   /   Friday, December 6th, 2019  /   Comments Off on Amgen gets approval for arthritis drug biosimilar

    Print       Email
Biotech giant Amgen received its third U.S. approval for a biosimilar Dec. 6, a competitor for Johnson & Johnson rheumatoid arthritis drug Remicade. Worldwide sales of Remicade have fallen 18 percent in the first nine months of 2019 to $3.35 billion, but still make up more than 10 percent of Johnson & Johnson’s pharmaceutical revenue.…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Limoneira, Calavo both report earnings growth as produce industry continues recovery

Read More →